RDDT Laboratories, a trading division of RMIT Drug Discovery Technologies Pty Ltd is a privately owned GLP accredited preclinical safety and bioanalytical testing company based in Melbourne, Australia.
Since being awarded its GLP accreditation in 2004, RDDT Laboratories is equipped to execute a range of toxicology studies (including genotoxicity, acute to chronic repeat dose studies etc) in various mammalian species in accordance to the appropriate regulatory standards. In addition, custom efficacy studies can be validated and performed to meet your needs. RDDT Laboratories also works closely with a number of partner Contract Research Organisations (CROs) to provide services in non-mammalian species.
RDDT Laboratories ensures excellent regulatory compliance based on OECD Guidelines in order to deliver the highest quality data to assist clients with their FDA, EMEA, TGA and other regulatory submissions. RDDT Laboratories' quality system adheres to OECD Guidelines and US FDA 21CFR Part 58 GLP requirements.
RDDT Laboratories' team consists of experienced professionals operating in state-of-the-art laboratory facilities including a new animal house. RDDT Laboratories take enormous pride in the quality of the services they offer, which meet the highest scientific standards, they strive to keep costs low, develop strong and lasting partnerships with all its clients, and studies to be done in a timely manner.